Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer.

Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM
Clin Cancer Res. 2013 19 (3): 538-40

PMID: 23344262 · DOI:10.1158/1078-0432.CCR-12-2745

Pancreatic ductal adenocarcinoma is the most aggressive of all epithelial malignancies. In contrast to the favorable trends seen in most other common malignancies, the five-year survival of patients with this disease remains only 6%, a statistic that has changed minimally for decades. Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) for use in pancreatic cancer in the last 15 years, and there are no established strategies for early detection.

MeSH Terms (6)

Biological Specimen Banks Biomarkers, Tumor Carcinoma, Pancreatic Ductal Clinical Trials as Topic Humans Pancreatic Neoplasms

Connections (2)

This publication is referenced by other Labnodes entities: